ATC Group: R05DB21 Cloperastine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R05DB21 in the ATC hierarchy

Level Code Title
1 R Respiratory system
2 R05 Cough and cold preparations
3 R05D Cough suppressants, excl. combinations with expectorants
4 R05DB Other cough suppressants
5 R05DB21 Cloperastine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 60 mg

Active ingredients in R05DB21

Active Ingredient Description
Cloperastine

Cloperastine is an antitussive and antihistamine that is marketed as a cough suppressant. The precise mechanism of action of cloperastine is not fully clear, but several different biological activities have been identified for the drug, of which include: ligand of the gamma1 receptor (Ki = 20 nM) (likely an agonist), GIRK channel blocker (described as “potent”), antihistamine (Ki = 3.8 nM for the H1 receptor), and anticholinergic. Cloperastine possesses dual activity. It also acts as a mild bronchorelaxant and has antihistaminic activity, without acting on the central nervous system or the respiratory center.

Medicines in this ATC group

Brazil (BR)

Ecuador (EC)

Hong Kong (HK)

Japan (JP)

Mexico (MX)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.